Lumvoa study designs: THRIVE and THRIVE-2

Lumvoa™ (veligrotug-vvze): studied in the largest and broadest population of thyroid eye disease (TED) patients to date^1-3*

Lumvoa was evaluated in 301 patients across 2 randomized, double-masked, placebo-controlled studies: active TED (THRIVE) and chronic TED (THRIVE-2). Patients were randomized in a 2:1 ratio to receive either Lumvoa or placebo. Patients in the Lumvoa group were given a 10 mg/kg dose every 3 weeks for a total of 5 infusions.¹

THRIVE (n=113)
Recent-onset active TED patients^1,4

Moderate-to-severe active TED with ≥3 mm excess proptosis

CAS ≥3 in study eye

Recent onset of TED signs and symptoms

THRIVE-2 (n=188)
Chronic TED patients^1,5

Moderate-to-severe chronic TED with ≥3 mm excess proptosis

All CAS (0-7) in study eye

Chronic TED signs and symptoms

*Based on completed Phase 3 trials in thyroid eye disease.

CAS=clinical activity score.

THRIVE and THRIVE-2 Phase 3 trial design^4,6,7

Patient baseline characteristics^4,6

	THRIVE		THRIVE-2
	Lumvoa (n=75)	Placebo (n=38)	Lumvoa (n=125)	Placebo (n=63)
Age, mean years	48.9	49.1	50.5	50.7
Female (%)	75.0	82.0	76.0	73.0
Proptosis, mean mm	23.2	23.2	24.3	23.8
Diplopia at baseline (%)	67.0	68.0	52.0	59.0
Time since TED onset, mean months	8.2	7.6	69.8	81.7

	THRIVE
	Lumvoa (n=75)	Placebo (n=38)
Age, mean years	48.9	49.1
Female (%)	75.0	82.0
Proptosis, mean mm	23.2	23.2
Diplopia at baseline (%)	67.0	68.0
Time since TED onset, mean months	8.2	7.6

	THRIVE-2
	Lumvoa (n=125)	Placebo (n=63)
Age, mean years	50.5	50.7
Female (%)	76.0	73.0
Proptosis, mean mm	24.3	23.8
Diplopia at baseline (%)	52.0	59.0
Time since TED onset, mean months	69.8	81.7

Request a Viridian representative to help you with any clinical or access questions

Request a representative

Indication: Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Important Safety Information

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients, of whom one-half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Lumvoa (500 mg) is an injection for infusion.

Please see accompanying Full Prescribing Information.

Lumvoa™ (veligrotug-vvze). Prescribing Information. Viridian Therapeutics, Inc; 2026.
Tepezza® (teprotumumab-trbw). Prescribing Information. Amgen Inc; 2025.
Data on file. TED trial combined search results. Feb 18, 2026. Viridian Therapeutics, Inc; 2026.
Yen MT, Cockerham K, Saeed P, et al. THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease. Ophthalmology. 2026. doi:10.1016/j.ophtha.2026.04.022.
Cockerham K, Abrams J, Mandeville J, et al. Chronic thyroid eye disease (TED) THRIVE-2 phase 3 trial of veligrotug (VRDN-001): efficacy, safety, and quality of life at 15 weeks. Presented at: American Academy of Ophthalmology Annual Meeting; Oct 18-20, 2025; Orlando, FL.
Cockerham K, Tang R, Mandeville J, et al. THRIVE and THRIVE-2 phase 3 trials: efficacy and safety of veligrotug (VRDN-001), a full antagonist antibody to IGF-1R, in thyroid eye disease (TED). Presented at: North American Neuro-Ophthalmology Society Annual Meeting; March 15-20, 2025; Tucson, AZ.
Data on file. Clinical study report: THRIVE-2 (Protocol VRDN-001-301). Viridian Therapeutics, Inc; 2025.